Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
about
Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease.Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.A school of red herring.Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedsideGd-encapsulated carbonaceous dots with efficient renal clearance for magnetic resonance imaging.Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study.Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update.Contemporary management of atherosclerotic renovascular disease: before and after ASTRAL.Diagnosis and management of urothelial carcinoma of the bladder.Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?Revisiting renovascular imaging for renal sympathetic denervation: current techniques and applications.Cardiac magnetic resonance imaging as a prognostic tool in patients with nonischemic cardiomyopathy.Use of blood pool agents with steady-state MRI to assess the vascular system.Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestationIncidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Controversies in Diagnosis of Pulmonary Embolism
P2860
Q30419214-BEEE6450-2B0A-4E6E-9408-91DB0D68FE82Q33805280-2F73F04A-332B-4BA6-BB31-E439BA24CC6FQ34395390-D4DE2767-A42F-4C19-8337-FF438B88E571Q36379549-05BBAC96-386C-4E01-8F4E-BF1D8C46C417Q36948085-7AB109B2-2E44-4945-8C8A-71D66DD5184AQ37452679-875A5B78-B8E2-4BB1-9D58-011CEC0045DDQ37862575-300B5CE8-2ABF-43D7-B52E-57A9CEE9908AQ37873966-00059F3E-4C7F-48A2-853F-51B43A94E3CBQ37874887-09EEA517-B790-4325-9328-86ECB3A1F047Q37948629-C18E4CAE-2CF4-4CBE-8A11-CF56A730E586Q38243984-BDA829B0-B65B-428A-BFE2-8EB39ED2B2CEQ38274908-932C10D5-3C1B-4EBD-8C76-7E2B3BE3CA16Q39250421-C7993383-EFE9-4575-B4E2-1A57F50118A2Q41112059-1C8C36A8-5703-41B2-BF7F-6F9DFE3E0E3DQ50999837-198EA07B-6470-4921-A7DD-534F239ECF5CQ55515077-AB2F11BC-5B2A-4D64-8C4F-5AD676AEFEBDQ57815179-BC11CB6C-FEE9-45FE-B310-73CDB32532DD
P2860
Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Low risk for nephrogenic syste ...... ed magnetic resonance imaging.
@ast
Low risk for nephrogenic syste ...... ed magnetic resonance imaging.
@en
type
label
Low risk for nephrogenic syste ...... ed magnetic resonance imaging.
@ast
Low risk for nephrogenic syste ...... ed magnetic resonance imaging.
@en
prefLabel
Low risk for nephrogenic syste ...... ed magnetic resonance imaging.
@ast
Low risk for nephrogenic syste ...... ed magnetic resonance imaging.
@en
P2093
P2860
P356
P1476
Low risk for nephrogenic syste ...... ed magnetic resonance imaging.
@en
P2093
Aladdin E Shurrab
Alan D Salama
Philip A Kalra
Sayed Husain
Steven Moser
P2860
P304
P356
10.2215/CJN.06580909
P577
2010-01-21T00:00:00Z